160 related articles for article (PubMed ID: 18279575)
21. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
Hammond-Thelin LA
Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
[TBL] [Abstract][Full Text] [Related]
23. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
Yarom N; Jonker DJ
Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
25. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.
Baas JM; Krens LL; Guchelaar HJ; Ouwerkerk J; de Jong FA; Lavrijsen AP; Gelderblom H
Cancer Treat Rev; 2012 Aug; 38(5):505-14. PubMed ID: 22100458
[TBL] [Abstract][Full Text] [Related]
26. [Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].
Jiang L; Xiao K; Long H
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan; 56(1):87-94. PubMed ID: 35092997
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
28. Targeting the epidermal growth factor receptor in solid tumors: focus on safety.
Lucchini E; Pilotto S; Spada E; Melisi D; Bria E; Tortora G
Expert Opin Drug Saf; 2014 May; 13(5):535-49. PubMed ID: 24684184
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
[TBL] [Abstract][Full Text] [Related]
30. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
Eaby B; Culkin A; Lacouture ME
Clin J Oncol Nurs; 2008 Apr; 12(2):283-90. PubMed ID: 18390464
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.
Pastore S; Lulli D; Girolomoni G
Arch Toxicol; 2014 Jun; 88(6):1189-203. PubMed ID: 24770552
[TBL] [Abstract][Full Text] [Related]
32. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
Vaubel J; Livingstone E; Schadendorf D; Zimmer L
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
34. Clinical management of EGFRI dermatologic toxicities: the European perspective.
Segaert S; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):22-6. PubMed ID: 18159647
[TBL] [Abstract][Full Text] [Related]
35. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
36. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
37. Dermatological side effects of current and upcoming targeted therapies in oncology.
Bonny M; Buyse V; Brochez L
Acta Clin Belg; 2011; 66(2):97-103. PubMed ID: 21630605
[TBL] [Abstract][Full Text] [Related]
38. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
LoRusso P
Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
Purdom M; Ohinata A
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
[TBL] [Abstract][Full Text] [Related]
40. [Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].
Livingstone E; Trarbach T; Zimmer L; Schuler M; Schadendorf D
Dtsch Med Wochenschr; 2011 Jan; 136(1-2):39-44. PubMed ID: 21181615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]